Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.
Lancet OncolSep 1, 2026
Clinical ResearchOncology (Medical)
Rafal Dziadziuszko, Jin Seok Ahn, Fabrice Barlesi et al.
✦ AI-curated · Sources linked
In 30 seconds
The ALINA trial, a phase 3 randomized controlled trial, evaluated adjuvant alectinib versus chemotherapy in patients with resected ALK-positive non-small-cell lung cancer (NSCLC). The study found that alectinib had a manageable safety profile and significantly improved health-related quality of life (HRQoL) over 2 years, with mean scores for mental and physical health reaching levels similar to the general population.
Key findings
- Alectinib showed fewer discontinuations due to adverse events (5%) compared to chemotherapy (13%).
- At week 12, alectinib improved bodily pain, role physical, mental health, social functioning, and vitality domains.
- At week 96, mean Mental Component Summary score was 49.9 and Physical Component Summary score was 48.8, comparable to population norms.
Why it matters
The findings highlight the potential of adjuvant alectinib to enhance quality of life in patients with resected ALK-positive NSCLC, alongside its established disease-free survival benefits, suggesting a shift in treatment standards.